Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2018 - IJCMAS--ICV 2018: 95.39 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2019) [Effective from January 1, 2019]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2018: 95.39
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2018: 95.39
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2017: 100.00
NAAS RATING 2018: 5.38

Int.J.Curr.Microbiol.App.Sci.2016.5(12): 383-388
DOI: http://dx.doi.org/10.20546/ijcmas.2016.512.042


CBNAAT: A Novel Tool for Rapid Detection of MTB and Rifampicin Resistance
V.P. Basavaraj1 and R. Rajani2*

 

Department of Microbiology, Raichur Institute of Medical Sciences, Raichur, Karnataka, India
*Corresponding author
Abstract:

Emergence of Multidrug resistant Tuberculosis (MDRTB) has become a significant obstacle for Tuberculosis (TB) control. Rifampicin (RIF) resistance is important indicator of MDRTB. Rapid simultaneous detection of Mycobacterium Tuberculosis (MTB) and RIF resistance are very essential for effective disease management. CBNAAT (Cartridge Based Nucliec Acid Amplification Test) also known as Gene Xpert MTB/RIF assay is a novel diagnostic tool for detection of MTB and RIF resistance. To study the usefulness of CBNAAT for rapid detection of MTB and RIF resistance in MDRTB suspected cases. 1201 sputum samples were collected from MDRTB suspected cases including both new cases and previously treated cases. These were processed using Gene Xpert MTB/RIF assay. The results were statistically analyzed. Out of 1201 sputum samples, MTB was detected in 268 (22.31%) samples and RIF resistance was detected in 30 (2.49%) samples. 2 (33.33%) RIF resistant samples were from failures, 14(12.17%) from Smear positive (S+) at diagnosis/retreatment case, 10(12.65%) from follow up S+, 1(0.11%) from HIV presumptive TB case. Combination of mutations ie mutations associated with more than one probe was seen in all the 30 RIF resistant samples. Mutations at 5 different rpoB gene regions are 100% at 518-523, 96.66% at 507-511, 90% at 512-518, 86.66% at 523-529 and 43.33% at 529-533. Gene Xpert MTB/RIF assay is a good screening tool for diagnosis of MTB and detection of RIF resistance from MDRTB suspected cases within a shorter period.


Keywords: MDRTB,Rifampicin resistance, GeneXpert MTB/RIF.
Download this article as Download

How to cite this article:

Basavaraj, V.P., and Rajani, R. 2016. CBNAAT: A Novel Tool for Rapid Detection of MTB and Rifampicin Resistance.Int.J.Curr.Microbiol.App.Sci. 5(12): 383-388. doi: http://dx.doi.org/10.20546/ijcmas.2016.512.042